Byterna Therapeutics Secures Tens of Millions in Pre-A Funding to Advance World’s First Circular mRNA In Vivo CAR-T Therapy

Recently, a pioneering enterprise in circular mRNA immunotherapyByterna Therapeutics(Byterna Therapeutics) announced the completion of a pre-A financing round worth tens of millions of yuan.

This round of financing not only secured participation from existing shareholdersYifeng Capital(Yifeng Zhuohua Fund) continues to increase its support and has also introduced a generative artificial intelligence (AI)-driven biopharmaceutical technology company.Insilico MedicineAwaiting new strategic investors.

The funds raised in this round will be primarily allocated to three key areas: accelerating the clinical trial applications for the world’s first dual-target circular mRNA in vivo CAR-T pipeline; advancing the development of the AI-personalized circular mRNA cancer vaccine pipeline; and co-establishing the next-generation mRNA AI-Native R&D Engine with Insilico Medicine, thereby enabling end-to-end intelligent capabilities from circular mRNA molecular design to clinical translation.

Byterna Therapeutics was established in 2023, co-founded by former Associate Professor Zeng Xian from the School of Pharmacy at Fudan University and Dr. Zhao Hui.

The company focuses on the development of next-generation RNA innovative drugs, striving to build a globally leading AI × circular RNA drug platform.

The company continues to deepen its expertise in core technological platforms, including AI-driven design, circular mRNA, and targeted LNP delivery. It is advancing original research and development in areas such as in vivo CAR-T, AI-enabled cancer immunotherapy, personalized cancer vaccines, and autoimmune diseases, thereby building a high-value, highly differentiated pipeline of circular RNA therapeutics.

Byterna Therapeutics' core competitiveness is reflected not only in the forward-looking nature of its AI technology platform, but also in tangible pipeline breakthroughs driven by AI.

One of the company's core pipelines isThe world’s first dual-target circular mRNA in vivo CAR-T therapy to enter clinical development is currently in an investigator-initiated clinical study.(IIT) stage. This milestone marks Byterna Therapeutics' official transition from a platform-based enterprise to the ranks of clinical-stage innovative pharmaceutical companies, further validating the feasibility of the technical approach of "achieving cell therapy effects through nucleic acid drug formats."

Another core pipeline is the AI-driven personalized circular mRNA cancer vaccine. This pipeline fully leverages AI’s precision in neoantigen prediction and combines it with the inherent advantages of circular mRNA in terms of stability and sustained expression in vivo, establishing an end-to-end R&D closed loop of “patient genomic data – AI sequence design – automated synthesis – personalized vaccine.” It aims to create a next-generation cancer vaccine solution that is more stable, more efficient, and more cost-effective than linear mRNA vaccines.

Join the reader exchange group:

Contact Us:wbfsh@staff.weibo.com